Pediatric Exclusivity For Brand Biologics Added In Senate FOB Provision, But Generics Have $1 Bil. In Leverage From CBO Score
Executive Summary
The roll-out of the health care reform bill now under debate in the Senate is a good news/bad news event for the generic industry
You may also be interested in...
Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?
The promise of health care savings from an abundance of biosimilar drugs brought to market under recently passed reforms may go unfulfilled if intellectual property provisions of the law aren't addressed, members of a panel at the BIO annual meeting in Chicago said May 5
Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?
The promise of health care savings from an abundance of biosimilar drugs brought to market under recently passed reforms may go unfulfilled if intellectual property provisions of the law aren't addressed, members of a panel at the BIO annual meeting in Chicago said May 5
Follow-On Biologics Politics: AARP's Rother Explains "What Beat Us"
Brand companies' argument that longer exclusivity would create more jobs needs to be countered with additional research and advocacy on industrial policy, Rother says at GPhA's annual meeting in Florida.